You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 298 No. 7, August 15, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (9)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Diabetes Mellitus
 •Cardiovascular Disease/ Myocardial Infarction
 •Alert me on articles by topic

Diabetes and Mortality Following Acute Coronary Syndromes

Sean M. Donahoe, MD; Garrick C. Stewart, MD; Carolyn H. McCabe, BS; Satishkumar Mohanavelu, MS; Sabina A. Murphy, MPH; Christopher P. Cannon, MD; Elliott M. Antman, MD

JAMA. 2007;298:765-775.

Context  The worldwide epidemic of diabetes mellitus is increasing the burden of cardiovascular disease, the leading cause of death among persons with diabetes. The independent effect of diabetes on mortality following acute coronary syndromes (ACS) is uncertain.

Objective  To evaluate the influence of diabetes on mortality following ACS using a large database spanning the full spectrum of ACS.

Design, Setting, and Patients  A subgroup analysis of patients with diabetes enrolled in randomized clinical trials that evaluated ACS therapies. Patients with ACS in 11 independent Thrombolysis in Myocardial Infarction (TIMI) Study Group clinical trials from 1997 to 2006 were pooled, including 62 036 patients (46 577 with ST-segment elevation myocardial infarction [STEMI] and 15 459 with unstable angina/non-STEMI [UA/NSTEMI]), of whom 10 613 (17.1%) had diabetes. A multivariable model was constructed to adjust for baseline characteristics, aspects of ACS presentation, and treatments for the ACS event.

Main Outcome Measures  Mortality at 30 days and 1 year following ACS among patients with diabetes vs patients without diabetes.

Results  Mortality at 30 days was significantly higher among patients with diabetes than without diabetes presenting with UA/NSTEMI (2.1% vs 1.1%, P < .001) and STEMI (8.5% vs 5.4%, P < .001). After adjusting for baseline characteristics and features and management of the ACS event, diabetes was independently associated with higher 30-day mortality after UA/NSTEMI (odds ratio [OR], 1.78; 95% confidence interval [CI], 1.24-2.56) or STEMI (OR, 1.40; 95% CI, 1.24-1.57). Diabetes at presentation with ACS was associated with significantly higher mortality 1 year after UA/NSTEMI (hazard ratio [HR], 1.65; 95% CI, 1.30-2.10) or STEMI (HR, 1.22; 95% CI, 1.08-1.38). By 1 year following ACS, patients with diabetes presenting with UA/NSTEMI had a risk of death that approached patients without diabetes presenting with STEMI (7.2% vs 8.1%).

Conclusion  Despite modern therapies for ACS, diabetes confers a significant adverse prognosis, which highlights the importance of aggressive strategies to manage this high-risk population with unstable ischemic heart disease.


Author Affiliations: The TIMI Study Group; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Drs Stewart, Cannon, and Antman, and Mr Mohanavelu and Mss McCabe and Murphy); and Department of Medicine, Division of Cardiology, Cornell University Medical Center, New York, New York (Dr Donahoe).


RELATED LETTERS

Diabetes and Mortality Risk After Acute Coronary Syndromes
Manivannan Srinivasan and Sumit Bhagra
JAMA. 2007;298(20):2367.
EXTRACT | FULL TEXT  

Diabetes and Mortality Risk After Acute Coronary Syndromes
Kapil Parakh
JAMA. 2007;298(20):2367-2368.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Therapy in Patients With STEMI
Harry P. Selker, Joanne Ingwall, and Charles E. Rackley
JAMA. 2008;299(20):2385.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Acute Coronary Syndromes
John L. Zeller, Alison E. Burke, and Richard M. Glass
JAMA. 2007;298(7):828.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Glucose-Insulin-Potassium Therapy in Patients With STEMI
Selker et al.
JAMA 2008;299:2385-2385.
FULL TEXT  

Impact of Drug-Eluting Stents Among Insulin-Treated Diabetic Patients: A Report From the National Heart, Lung, and Blood Institute Dynamic Registry
Mulukutla et al.
J Am Coll Cardiol Intv 2008;1:139-147.
ABSTRACT | FULL TEXT  

LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?
Nesto
Clin. Diabetes 2008;26:8-13.
ABSTRACT | FULL TEXT  

Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning
Ferdinandy et al.
Pharmacol. Rev. 2007;59:418-458.
ABSTRACT | FULL TEXT  

Diabetes and Mortality Risk After Acute Coronary Syndromes
Srinivasan and Bhagra
JAMA 2007;298:2367-2367.
FULL TEXT  

Diabetes and Mortality Risk After Acute Coronary Syndromes
Parakh
JAMA 2007;298:2367-2368.
FULL TEXT  

Diabetes Contributes to Acute Coronary Syndromes Death
DOC News 2007;4:15-15.
FULL TEXT  

Diabetes Increases Short-Term Mortality Risk in Patients with Acute Coronary Syndromes
JWatch Emergency Med. 2007;2007:2-2.
FULL TEXT  

Patients with Diabetes Fare Worse After MI Than Those Without Diabetes
Journal Watch Cardiology 2007;2007:4-4.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.